Skip to content

Association of Post-Dexamethasone Cortisol With Cardiovascular and Metabolic Comorbidities in Patients With Nonfunctioning Adrenal Adenomas.

Oct 2026 · Endocrine Practice · 0 citations · 20 references
Medicine

TL;DR

Higher post-DST cortisol within the suppressed range was independently associated with documented ASCVD and showed substantial discrimination, which support a cardiometabolic gradient below the mild autonomous cortisol secretion threshold but do not establish a diagnostic cutoff.

Abstract

Objective

To determine whether post-dexamethasone suppression test (DST) cortisol within the conventionally suppressed range is associated with documented atherosclerotic cardiovascular disease (ASCVD) and cardiometabolic comorbidities in nonfunctioning adrenal adenomas (NFAAs).

Methods

This retrospective single-center study included 444 adults with homogeneous adrenal lesions smaller than 4 cm, unenhanced computed tomography attenuation of 10 Hounsfield units or less, no adrenal hormone excess, and post-1 mg DST cortisol of 1.8 μg/dL or less. Documented ASCVD was the primary outcome; metabolic syndrome and other cardiometabolic conditions were secondary outcomes. ROC analysis and multivariable logistic regression were performed, with cortisol modeled per 0.1 μg/dL increase.

Results

Women comprised 69.6% of the cohort; median age was 57 years and median post-DST cortisol was 0.96 μg/dL. Each 0.1 μg/dL increase was independently associated with 21% higher odds of documented ASCVD (adjusted odds ratio, 1.21; 95% CI, 1.09-1.34; P<.001). The ROC area under the curve was 0.820 (95% CI, 0.781-0.860). The exploratory Youden-optimal value was 0.985 μg/dL, with 87% sensitivity, 71% specificity, 59% positive predictive value, and 92% negative predictive value. Post-DST cortisol was also independently associated with metabolic syndrome (adjusted odds ratio, 1.24; 95% CI, 1.13-1.35; P<.001).

Conclusion

Higher post-DST cortisol within the suppressed range was independently associated with documented ASCVD and showed substantial discrimination. These findings support a cardiometabolic gradient below the mild autonomous cortisol secretion threshold but do not establish a diagnostic cutoff.

View source

Similar papers

Sep 2026

The cardiometabolic significance of post-dexamethasone cortisol levels below the MACS threshold in adrenal incidentaloma

The findings suggest that patients below the current MACS threshold may not represent a metabolically homogeneous or uniformly benign population and support further prospective investigation of cardiometabolic risk across the continuum of post-DST cortisol levels.

Elif Seray Korkmaz, Birsen Öztürk Gökçe, M. Kebapçı · 0 citations
Open access Sep 2026

Adrenal incidentalomas: 1 mg dexamethasone test result in the context of cardiometabolic risk.

Post-DST cortisol concentrations below the standard cutoff may be associated with cardiometabolic comorbidities in patients with adrenal incidentalomas, and these findings should be interpreted with caution and require confirmation in prospective studies.

J. Kokoszka, M. Opalińska, Magdalena Fiema et al. · 0 citations
Open access Oct 2026

Post-dexamethasone cortisol levels in non-functioning adrenal incidentalomas: a pooled individual participant data analysis

Comparing F-1mgDST distributions between individuals with NFAI and population-based controls and to explore whether alternative F-1mgDST thresholds would meaningfully modify patient classification found no F-1mgDST threshold with an accuracy exceeding 60% for distinguishing controls from patients with NFAI.

I. Chiodini, V. Favero, C. Eller-Vainicher et al. · 0 citations
Open access Sep 2026

Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study

Hypercortisolism and type 2 diabetes mellitus (T2D) independently contribute to an increased burden of cardiometabolic morbidity and mortality. However, data on the interaction of hypercortisolism and T2D are scarce—thus, we aimed to assess the cortisol-associated morbidity and mortality in the context of T2D and adren...

Luise Bellach, S. Hofer-Zeni, Dorota Sluková et al. · 0 citations
Open access Oct 2026

Mild Autonomous Cortisol Secretion and Psychiatric Morbidity in Patients With Adrenal Tumors: A Cohort Study.

CONTEXT Mild autonomous cortisol secretion (MACS) in adrenal tumors (ATs) is associated with cardiometabolic disease, but its relationship with psychiatric morbidity is poorly defined. OBJECTIVE To investigate psychiatric outcomes in relation to cortisol autonomy in patients with ATs. METHODS Population-based retro...

Hadis Mirzaei, J. Lindh, Alexandra Falhammar et al. · 0 citations
Sep 2026

Cardiometabolic benefits after adrenalectomy for mild autonomous cortisol secretion.

BACKGROUND Mild autonomous cortisol secretion causes substantial cardiometabolic morbidity, yet evidence for benefits following adrenalectomy remains mixed. Prior studies are limited by small sample sizes and heterogeneous definitions. This study evaluates the metabolic impact of adrenalectomy compared with nonoperativ...

Alexis Korman, J. Done, Arden Stromnes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.